These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 39167623)

  • 41. Afatinib versus methotrexate as second-line treatment in Asian patients with recurrent or metastatic squamous cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 3): an open-label, randomised phase III trial.
    Guo Y; Ahn MJ; Chan A; Wang CH; Kang JH; Kim SB; Bello M; Arora RS; Zhang Q; He X; Li P; Dechaphunkul A; Kumar V; Kamble K; Li W; Kandil A; Cohen EEW; Geng Y; Zografos E; Tang PZ
    Ann Oncol; 2019 Nov; 30(11):1831-1839. PubMed ID: 31501887
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Comparative long-term outcomes of pembrolizumab plus chemotherapy versus pembrolizumab monotherapy as first-line therapy for metastatic non-small-cell lung cancer: a systematic review and network meta-analysis.
    Huang S; Huang Z; Huang X; Luo R; Liang W; Qin T
    Front Immunol; 2024; 15():1375136. PubMed ID: 39072325
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Safety evaluation of pembrolizumab for treating recurrent head and neck squamous cell carcinoma.
    Desilets A; Soulières D
    Expert Opin Drug Saf; 2020 Aug; 19(8):927-934. PubMed ID: 32458764
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The use of pembrolizumab monotherapy for the management of head and neck squamous cell carcinoma (HNSCC) in the UK.
    Vasiliadou I; Grose D; Wilson C; Thapa A; Donnelly O; Lee E; Leslie I; Karim M; Hartley A; Partridge S; Medlow K; De Boisanger J; Metcalf R; Williamson A; Haridass A; Noble D; Mactier K; Walter H; Ma N; De Winton E; Cohen J; Rayner L; Geropantas K; Jankowska P; Mason J; Moleron R; Laws K; Ulahannan D; Nallathambi C; Michaelidou A; Nallamilli S; Raouf S; Palmer K; Bienz M; Karet T; Khalique S; Paterson C; Harrington K; Bhide S; Kong A
    Int J Cancer; 2024 Sep; 155(5):883-893. PubMed ID: 38685816
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label phase III study.
    Ferris RL; Haddad R; Even C; Tahara M; Dvorkin M; Ciuleanu TE; Clement PM; Mesia R; Kutukova S; Zholudeva L; Daste A; Caballero-Daroqui J; Keam B; Vynnychenko I; Lafond C; Shetty J; Mann H; Fan J; Wildsmith S; Morsli N; Fayette J; Licitra L
    Ann Oncol; 2020 Jul; 31(7):942-950. PubMed ID: 32294530
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Concurrent Definitive Immunoradiotherapy for Patients with Stage III-IV Head and Neck Cancer and Cisplatin Contraindication.
    Weiss J; Sheth S; Deal AM; Grilley Olson JE; Patel S; Hackman TG; Blumberg JM; Galloway TJ; Patel S; Zanation AM; Shen CJ; Hayes DN; Hilliard C; Mehra R; McKinnon KP; Wang HH; Weissler MC; Bauman JR; Chera BS; Vincent BG
    Clin Cancer Res; 2020 Aug; 26(16):4260-4267. PubMed ID: 32371539
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A phase II study of poziotinib in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.
    Lee JH; Heo SG; Ahn BC; Hong MH; Cho BC; Lim SM; Kim HR
    Cancer Med; 2021 Oct; 10(20):7012-7020. PubMed ID: 34528763
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Afatinib versus methotrexate in older patients with second-line recurrent and/or metastatic head and neck squamous cell carcinoma: subgroup analysis of the LUX-Head & Neck 1 trial.
    Clement PM; Gauler T; Machiels JP; Haddad RI; Fayette J; Licitra LF; Tahara M; Cohen EE; Cupissol D; Grau JJ; Guigay J; Caponigro F; de Castro G; de Souza Viana L; Keilholz U; Del Campo JM; Cong XJ; Ehrnrooth E; Vermorken JB;
    Ann Oncol; 2016 Aug; 27(8):1585-93. PubMed ID: 27084954
    [TBL] [Abstract][Full Text] [Related]  

  • 49. First-line treatment with chemotherapy plus cetuximab in Chinese patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: Efficacy and safety results of the randomised, phase III CHANGE-2 trial.
    Guo Y; Luo Y; Zhang Q; Huang X; Li Z; Shen L; Feng J; Sun Y; Yang K; Ge M; Zhu X; Wang L; Liu Y; He X; Bai C; Xue K; Zeng Y; Chang X; Chen W; Lin T
    Eur J Cancer; 2021 Oct; 156():35-45. PubMed ID: 34418665
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial.
    Choueiri TK; Escudier B; Powles T; Tannir NM; Mainwaring PN; Rini BI; Hammers HJ; Donskov F; Roth BJ; Peltola K; Lee JL; Heng DYC; Schmidinger M; Agarwal N; Sternberg CN; McDermott DF; Aftab DT; Hessel C; Scheffold C; Schwab G; Hutson TE; Pal S; Motzer RJ;
    Lancet Oncol; 2016 Jul; 17(7):917-927. PubMed ID: 27279544
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Pembrolizumab plus nab-paclitaxel and platinum as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma: a prospective phaseⅡstudy].
    Chen XR; Xie ZC; Lu HZ; Yang JL; Gui L
    Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2024 Apr; 59(4):321-328. PubMed ID: 38599639
    [No Abstract]   [Full Text] [Related]  

  • 52. Nivolumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: Efficacy and Safety in CheckMate 141 by Prior Cetuximab Use.
    Ferris RL; Licitra L; Fayette J; Even C; Blumenschein G; Harrington KJ; Guigay J; Vokes EE; Saba NF; Haddad R; Ramkumar S; Russell J; Brossart P; Tahara M; Colevas AD; Concha-Benavente F; Lynch M; Li L; Gillison ML
    Clin Cancer Res; 2019 Sep; 25(17):5221-5230. PubMed ID: 31239321
    [TBL] [Abstract][Full Text] [Related]  

  • 53. First-line pembrolizumab plus chemotherapy for advanced/metastatic esophageal cancer: 1-year extended follow-up in the Japanese subgroup of the phase 3 KEYNOTE-590 study.
    Kato K; Kojima T; Hara H; Tsuji A; Yasui H; Muro K; Satoh T; Ogata T; Ishihara R; Goto M; Baba H; Nishina T; Han S; Iwakami K; Yatsuzuka N; Doi T
    Esophagus; 2024 Jul; 21(3):306-318. PubMed ID: 38607538
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Phase II and Biomarker Study of Cabozantinib in Metastatic Triple-Negative Breast Cancer Patients.
    Tolaney SM; Ziehr DR; Guo H; Ng MR; Barry WT; Higgins MJ; Isakoff SJ; Brock JE; Ivanova EV; Paweletz CP; Demeo MK; Ramaiya NH; Overmoyer BA; Jain RK; Winer EP; Duda DG
    Oncologist; 2017 Jan; 22(1):25-32. PubMed ID: 27789775
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pembrolizumab plus azacitidine in patients with chemotherapy refractory metastatic colorectal cancer: a single-arm phase 2 trial and correlative biomarker analysis.
    Kuang C; Park Y; Augustin RC; Lin Y; Hartman DJ; Seigh L; Pai RK; Sun W; Bahary N; Ohr J; Rhee JC; Marks SM; Beasley HS; Shuai Y; Herman JG; Zarour HM; Chu E; Lee JJ; Krishnamurthy A
    Clin Epigenetics; 2022 Jan; 14(1):3. PubMed ID: 34991708
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A Phase I/II Clinical Trial of Pembrolizumab and Cabozantinib in Metastatic Renal Cell Carcinoma.
    Kessler ER; Callihan E; Hu J; Eule C; Srivastava G; Kemme DJ; Iruku P; Rana V; Moore J; Schuster SR; Amirault M; Flaig TW; Lam ET
    Cancer Res Commun; 2023 Jun; 3(6):1004-1012. PubMed ID: 37377613
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression.
    Ferris RL; Blumenschein G; Fayette J; Guigay J; Colevas AD; Licitra L; Harrington KJ; Kasper S; Vokes EE; Even C; Worden F; Saba NF; Docampo LCI; Haddad R; Rordorf T; Kiyota N; Tahara M; Lynch M; Jayaprakash V; Li L; Gillison ML
    Oral Oncol; 2018 Jun; 81():45-51. PubMed ID: 29884413
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cabozantinib in Patients with Advanced Merkel Cell Carcinoma.
    Rabinowits G; Lezcano C; Catalano PJ; McHugh P; Becker H; Reilly MM; Huang J; Tyagi A; Thakuria M; Bresler SC; Sholl LM; Shapiro GI; Haddad R; DeCaprio JA
    Oncologist; 2018 Jul; 23(7):814-821. PubMed ID: 29445030
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Finotonlimab with chemotherapy in recurrent or metastatic head and neck cancer: a randomized phase 3 trial.
    Shi Y; Guo W; Wang W; Wu Y; Fang M; Huang X; Han P; Zhang Q; Dong P; Zhou X; Peng H; Hu C; Chen X; Zhang S; Chang Z; Li X; Ding Y; Qu S; Jing S; Zhang S; Gui L; Sun Y; Wang L; Liu Y; Wu H; Li G; Fu Z; Shi J; Jiang H; Bai Y; Cui J; Zheng Y; Cui W; Jia X; Zhai L; Cai Q; Xiong D; Wu Y; Cao J; Wu R; Hu G; Peng L; Xie L; Gai W; Wang Y; Su Y
    Nat Med; 2024 Sep; 30(9):2568-2575. PubMed ID: 38942993
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Efficacy and toxicity of immune checkpoint inhibitors combination therapy for advanced renal cell carcinoma: a systematic review and network meta-analysis.
    Chen X; Xu Z; Wu C; Xie L; Wang P; Liu X
    Front Immunol; 2024; 15():1255577. PubMed ID: 38390328
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.